ACM
BPMC

ADAR1 Capital Management’s Blueprint Medicines BPMC Stock Holding History

ADAR1 Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$1.92M – 227
2025
Q2 		$1.92M Buy
+15,000
New +$1.56M 0.29% 57
2024
Q4 		– Sell
-5,100
Closed -$472K – 233
2024
Q3 		$472K Buy
+5,100
New +$507K 0.08% 120

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ADAR1 Capital Management's BPMC Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 15,000 shares — an estimated $1.92M sold.

ADAR1 Capital Management first reported a position in BPMC in Q3 2024 and held it in 2 quarters. The position peaked at $1.92M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 15,000 Blueprint Medicines shares in Q3 2025, an estimated $1.92M.
  • ADAR1 Capital Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 2 quarters.
  • ADAR1 Capital Management's Blueprint Medicines position peaked at $1.92M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.